Hardin Scientific Locates Manufacturing-Development Campus in Greensburg, Kentucky
01/26/2018
The company will locate in a 40,000-square-foot spec building in Greensburg, 74 miles northeast of Bowling Green, where it will manufacture T3-i7 Cell-Culture incubators, the first modular and internet-enabled device on the company’s platform. The device enables accurate reproduction of human-like body conditions for tissue culture, stem-cell research, protein expressions and genetics in the research, diagnostic and forensic industries.
Founder & CEO Aaron Hardin, a Berea, Kentucky native, noted the Greensburg community’s hospitality and the logistical advantages of locating in Kentucky as major factors in the company decision.
“There is a technological void in the life sciences; the people creating life-saving treatments and pharmaceuticals rely on outdated equipment,” Hardin said. “What they do with the tools they have is truly amazing, and I look forward to what they can accomplish with 21st Century solutions. Bringing this project to Kentucky makes good business sense and the ability to stimulate economic growth in my home state feels right. We received two dozen state and city proposals and searched the globe, but I can’t think of a more dedicated, harder working and humble labor force available.”
To encourage the investment and job growth in the community, the Kentucky Economic Development Finance Authority (KEDFA) in January preliminarily approved the company for tax incentives up to $1 million through the Kentucky Business Investment program. The performance-based incentive allows a company to keep a portion of its investment over the agreement term through corporate income tax credits and wage assessments by meeting job and investment targets. In addition, Hardin Scientific can receive resources from the Kentucky Skills Network.
Hardin founded the company in 2016 with the mission to reduce human suffering through the elimination of disease, removal of barriers and an increase in the rate of discovery. He said the impetus for creating Hardin Scientific was a realization that “innovators weren’t being innovated,” noting the primary reason for high-cost prescription drugs is that equipment used in developing medications has become obsolete.
Hardin Scientific’s T3-i7 technology helps to reduce the gap between equipment and treatment technology. Its patented health-monitoring system helps to safeguard samples and ensure a higher level of safety and security.
“Hardin Scientific combines cutting-edge science with the kind of business initiative we want to encourage more of in Kentucky,” said Governor Matt Bevin. “Companies like this are fueling our state’s rise to national distinction in research and advanced manufacturing. It is the entrepreneurs with big ideas, like those guiding Hardin Scientific, that are making this happen. It is great to see a homegrown product of one of Kentucky’s universities leading the way as we move into the future.”
Project Announcements
Kikkoman Foods Plans Jefferson, Wisconsin, Operations
04/26/2024
BWX Technologies Expands Cambridge, Ontario, Nuclear Production Operations
04/26/2024
Greenheck Group Plans Knoxville, Tennessee, Operations
04/26/2024
Local Bounti Plans Pasco, Washington, Indoor Agricultural Operations
04/26/2024
Innovative Construction Group Plans Siler City, North Carolina, Production Operations
04/26/2024
Crystal Window and Door Systems Plans Mansfield, Texas, Headquarters-Production Operations
04/25/2024
Most Read
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
38th Annual Corporate Survey: Are Unrealized Predictions of an Economic Slump Leading Small to Mid-Size Companies to Put Off Expansion Plans?
Q1 2024
-
Making Hybrid More Human in 2024
Q1 2024
-
Manufacturing Momentum Is Building
Q1 2024
-
20th Annual Consultants Survey: Clients Prioritize Access to Skilled Labor, Responsive State & Local Government
Q1 2024
-
Public-Private Partnerships Incentivize Industrial Development
Q1 2024